The Evermay Wealth Management LLC Sells 168 Shares of Laboratory Corp. of America Holdings (LH)

The Evermay Wealth Management LLC Sells 168 Shares of Laboratory Corp. of America Holdings (LH)

Evermay Wealth Management LLC lowered its stake in Laboratory Corp. of America Holdings (NYSE:LH) by 4.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 4,029 shares of the company’s stock after selling 168 shares during the period. Evermay Wealth Management LLC’s holdings in Laboratory Corp. of America Holdings were worth $554,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of LH. Robecosam AG increased its position in shares of Laboratory Corp. of America Holdings by 23.1% in the second quarter. Robecosam AG now owns 800 shares of the company’s stock valued at $104,000 after buying an additional 150 shares during the period. Smithfield Trust Co. acquired a new position in shares of Laboratory Corp. of America Holdings during the second quarter valued at approximately $107,000. Roble Belko & Company Inc acquired a new position in shares of Laboratory Corp. of America Holdings during the second quarter valued at approximately $117,000. Integrated Investment Consultants LLC increased its position in shares of Laboratory Corp. of America Holdings by 16.4% in the third quarter. Integrated Investment Consultants LLC now owns 1,092 shares of the company’s stock valued at $149,000 after buying an additional 154 shares during the period. Finally, MSI Financial Services Inc increased its position in shares of Laboratory Corp. of America Holdings by 2.3% in the third quarter. MSI Financial Services Inc now owns 1,117 shares of the company’s stock valued at $154,000 after buying an additional 25 shares during the period. 91.22% of the stock is currently owned by institutional investors and hedge funds.

Laboratory Corp. of America Holdings (NYSE:LH) traded down 1.23% during midday trading on Thursday, reaching $132.74. The company’s stock had a trading volume of 641,530 shares. The stock’s 50-day moving average price is $128.85 and its 200 day moving average price is $133.18. The firm has a market capitalization of $13.67 billion, a PE ratio of 21.05 and a beta of 0.95. Laboratory Corp. of America Holdings has a 1-year low of $97.79 and a 1-year high of $141.32.

Laboratory Corp. of America Holdings (NYSE:LH) last issued its quarterly earnings data on Wednesday, October 26th. The company reported $2.25 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.29 by $0.04. Laboratory Corp. of America Holdings had a return on equity of 16.97% and a net margin of 6.85%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.38 billion. During the same period in the prior year, the company earned $2.07 EPS. The firm’s revenue was up 4.5% on a year-over-year basis. Equities analysts anticipate that Laboratory Corp. of America Holdings will post $8.80 EPS for the current fiscal year.

Several brokerages have commented on LH. Zacks Investment Research raised Laboratory Corp. of America Holdings from a “hold” rating to a “buy” rating and set a $153.00 price objective on the stock in a research report on Tuesday, October 4th. Canaccord Genuity set a $140.00 price objective on Laboratory Corp. of America Holdings and gave the company a “buy” rating in a research report on Tuesday. Deutsche Bank AG reaffirmed a “buy” rating and issued a $170.00 price objective on shares of Laboratory Corp. of America Holdings in a research report on Wednesday. Finally, Gabelli started coverage on Laboratory Corp. of America Holdings in a research report on Tuesday, October 25th. They issued a “buy” rating and a $180.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Laboratory Corp. of America Holdings currently has an average rating of “Buy” and a consensus target price of $146.40.

Laboratory Corp. of America Holdings Company Profile

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Related posts

Leave a Comment